Terlipressin Administration for Bleeding Esophageal Varices and Septic Shock

Mechanism of Action and Clinical Use

Terlipressin, a vasopressin analog, reduces splanchnic blood flow and portal pressure, making it effective for controlling variceal bleeding in patients with esophageal varices, according to the World Journal of Emergency Surgery 1, 2
It works by causing vasoconstriction in the splanchnic circulation, which decreases portal venous inflow and lowers portal pressure, as reported by the World Journal of Emergency Surgery 2, 3
Terlipressin has a longer half-life and fewer adverse effects compared to vasopressin, making it more suitable for clinical use in patients with bleeding esophageal varices, as stated by the World Journal of Emergency Surgery 1, 2

Conventional dosing for variceal bleeding has been 2 mg IV bolus initially, followed by 1 mg IV every 4 hours, as recommended by Hepatology 4
Duration of treatment typically ranges from 2-5 days depending on clinical response in patients with esophageal varices, according to Hepatology 4

Recent evidence suggests continuous infusion at 4 mg/24 hours is superior to bolus administration for managing bleeding esophageal varices, as reported by Gastroenterology 5
Continuous infusion provides greater reduction in hepatic venous pressure gradient (85% vs 58% at 24 hours) and lower rebleeding rates between 2-5 days (2% vs 15%) in patients with esophageal varices, according to Gastroenterology 5
Continuous infusion results in fewer adverse events due to lower total dose requirements in patients with bleeding esophageal varices, as stated by Gastroenterology 5

The American College of Radiology recommends starting vasoactive drugs as soon as possible, even before diagnostic endoscopy, for patients with variceal bleeding or norepinephrine-resistant septic shock 4, 6
The preferred method of administration is continuous infusion at 4 mg/24 hours, as recommended by Gastroenterology 5
Alternative method is bolus dosing (2 mg initially, then 1 mg every 4 hours) if infusion pumps are unavailable, according to Hepatology 4

The American College of Radiology suggests combining terlipressin with endoscopic therapy (preferably endoscopic variceal ligation) for optimal outcomes in patients with bleeding esophageal varices 6, 7
A trial by Lo et al. showed that combination of EVL and terlipressin infusion for 2 days was superior to terlipressin alone for 5 days, as reported by the Journal of the American College of Radiology 7, 8

Terlipressin is contraindicated in patients with hypoxia, worsening respiratory symptoms, or ongoing coronary, peripheral, or mesenteric ischemia, as stated by Gastroenterology 5
Common adverse reactions include abdominal pain, nausea, respiratory failure, diarrhea, and dyspnea, according to Gastroenterology 5
Monitoring for hyponatremia, chest pain, and other cardiovascular complications is essential, as recommended by Gastroenterology 5

For patients with hepatorenal syndrome, terlipressin administration via bolus injection over 2 minutes is FDA-approved, but remains investigational for variceal bleeding, as reported by the Journal of the American College of Radiology 7
In patients with bleeding anorectal varices, the same principles apply regarding terlipressin administration, according to the World Journal of Emergency Surgery 1, 2